secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001104659-25-075189
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q2 revenue up 32% to $546.6M; raises FY2025 revenue outlook by $80M
--------------------------------------------------------------------------

- Total revenue $546.6M (+32.2% YoY); product revenue $544.4M (+32.3%).
- Oncology tests grew 50.6% to 188,800; total tests processed 853,100 (+12.2%).
- Achieved positive cash flow of ~$24.3M in Q2; cash and investments $1,016M.
- Net loss per diluted share ($0.74) vs ($0.30) in Q2 2024, impacted by $19.8M legal accruals.
- Raising 2025 revenue guidance to $2.02B-$2.10B from $1.94B-$2.02B; OpEx outlook unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925075189/0001104659-25-075189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925075189/tm2522162d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-075189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer